GlassScriptPhysician profile
Curtis D Converse
NPI 1013385061
$2,036.38
in general payments reported to CMS, 2019-2025
21 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $140 · 2021: $59.96 · 2022: $97.84 · 2023: $349 · 2024: $503 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.49 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $704.40 | 2019-2024 | |
| Glaxosmithkline, LLC. | $212.63 | 2019-2025 | Nucala, Shingrix, Arexvy |
| United Therapeutics Corporation | $192.23 | 2021-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $182.93 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $151.18 | 2019-2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $61.89 | 2024-2025 | Uptravi |
| Abbvie INC. | $58.62 | 2023-2024 | Teflaro, Dalvance, Avycaz |
| Biomerieux INC | $56.36 | 2024 | Filmarray Bcid Panel |
| Genzyme Corporation | $55.17 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $53.98 | 2022-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.98 | 2022-2024 | Ofev |
| Shionogi INC | $53.08 | 2025 | Fetroja |
| Abiomed | $34.83 | 2024 | Impella |
| La Jolla Pharmaceutical Company | $26.82 | 2025 | Giapreza |
| Baxter Healthcare | $25.52 | 2025 | Hillrom - Volara System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.26 | 2023 | Tezspire |
| Ambu INC. | $21.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.08 | 2023 | Xarelto |
| Intuitive Surgical, INC. | $19.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.61 | 2024 | Fasenra |
| Edwards Lifesciences Corporation | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Converse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.